Mesothelioma Market is Expected to Showcase Significant Growth by 2030, Predicts DelveInsight | Key Companies – Merck, Trizell, Takeda, AstraZeneca, Roche, PharmaMar, Pfizer, Merck, and Others

December 14 22:34 2021
Mesothelioma Market is Expected to Showcase Significant Growth by 2030, Predicts DelveInsight | Key Companies - Merck, Trizell, Takeda, AstraZeneca, Roche, PharmaMar, Pfizer, Merck, and Others
Delveinsight Business Research LLP
DelveInsight’s “Mesothelioma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Mesothelioma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Mesothelioma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Mesothelioma Market

Mesothelioma: An Overview

Mesothelioma is a rare, aggressive form of malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen, or heart. There are four primary types of mesothelioma based on tumor location are Pleural Mesothelioma (MPM), Peritoneal Mesothelioma, Pericardial Mesothelioma, and Testicular Mesothelioma.

Pleural mesothelioma is a cancer of the pleura, which is the mesothelium surrounding the lungs and it is the most common type of mesothelioma, accounting for 80 – 90% of all diagnosed cases. Because males is exposed to asbestos more often, they are more likely to be diagnosed with mesothelioma.

Mesothelioma Market Key Facts

  • The total incident cases of Mesothelioma in the 7MM were observed to be 13,028 cases in 2017 which are estimated to decline during the study period (2017-2030).

  • Mesothelioma incidence rates in most of the 7MM countries (except Spain and Japan) are in the declining trend due to reduced population-wide exposure to asbestos. Among the European Countries, the highest Mesothelioma incident cases were observed in the UK in 2017.

  • In EU-5 countries, the highest number of incident cases of Mesothelioma was found in the United Kingdom with 2,804 cases in 2017, followed by Germany and Italy. Spain accounted for the least number of incident cases, i.e., 524 cases in 2017.

  • As per the Delveinsight, the United States accounted for nearly 3,200 mesothelioma cases for the year 2017.

Get the sample copy of the report at Mesothelioma Therapeutics Market

Mesothelioma Market

As per DelveInsight’s estimate, among the 7MM countries, the United States accounted for the highest market size in 2017.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Mesothelioma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Mesothelioma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Mesothelioma Epidemiology

The epidemiology section covers insights about the historical and current Mesothelioma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Mesothelioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mesothelioma market or expected to get launched in the market during the study period. The analysis covers Mesothelioma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Mesothelioma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Mesothelioma Therapeutics Analysis

The dynamics of the Mesothelioma market is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in R&D activities.

Key Companies in the Mesothelioma Market includes:

  • Merck Sharp & Dohme Corp.

  • Trizell

  • AstraZeneca

  • Amphera BV

  • Polaris Pharmaceuticals

  • Hoffmann-La Roche

  • Sellas Life Sciences Group

  • Momotaro-Gene

  • PharmaMar

  • Boehringer Ingelheim Limited

  • Pfizer 

  • Merck KGaA

  • Sumitomo Dainippon Pharma

  • Bayer

  • ImmunoGen

  • MorphoSys

  • Targovax

  • Kissei Pharmaceutical

  • TCR2 Therapeutics

  • Atara Biotherapeutics

  • Bellicum Pharmaceuticals

  • Takeda (Millennium Pharmaceuticals)

And many others

Mesothelioma Therapies covered in the report include:

  • TR002

  • TC-210

  • ONCOS-102

  • Alisertib (MLN8237)

  • Imfinzi

  • Anetumab Ravtansine (BAY 94-9343)

  • Tecentriq Plus Avastin

  • MesoPher

  • Pegargiminase

  • YS110

  • iCasp9M28z

  • Napabucasin

  • Galinpepimut-S (Vaccine)

  • Lurbinectedin

  • MTG201 Plus Nivolumab

  • Yondelis (trabectedin)

  • Nintedanib

  • Avelumab

And many more

Request for Sample Report @ Mesothelioma Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Mesothelioma Competitive Intelligence Analysis

4. Mesothelioma Market Overview at a Glance

5. Mesothelioma Disease Background and Overview

6. Mesothelioma Patient Journey

7. Mesothelioma Epidemiology and Patient Population

8. Mesothelioma Treatment Algorithm, Current Treatment, and Medical Practices

9. Mesothelioma Unmet Needs

10. Key Endpoints of Mesothelioma Treatment

11. Mesothelioma Marketed Products

12. Mesothelioma Emerging Therapies

13. Mesothelioma Seven Major Market Analysis

14. Attribute Analysis

15. Mesothelioma Market Outlook (7 major markets)

16. Mesothelioma Access and Reimbursement Overview

17. KOL Views on the Mesothelioma Market.

18. Mesothelioma Market Drivers

19. Mesothelioma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get the sample copy of the report at:

Latest Reports by DelveInsight

Malignant Pleural Mesothelioma (MPM) Market

DelveInsight’s Malignant Pleural Mesothelioma (MPM) – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the market size, share, trends, epidemiology, emerging therapies, and key companies in the domain.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States